320 related articles for article (PubMed ID: 18093335)
21. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
Fadul CE; Fisher JL; Hampton TH; Lallana EC; Li Z; Gui J; Szczepiorkowski ZM; Tosteson TD; Rhodes CH; Wishart HA; Lewis LD; Ernstoff MS
J Immunother; 2011 May; 34(4):382-9. PubMed ID: 21499132
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response.
Okada H; Pollack IF; Lieberman F; Lunsford LD; Kondziolka D; Schiff D; Attanucci J; Edington H; Chambers W; Kalinski P; Kinzler D; Whiteside T; Elder E; Potter D
Hum Gene Ther; 2001 Mar; 12(5):575-95. PubMed ID: 11268289
[No Abstract] [Full Text] [Related]
24. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
[TBL] [Abstract][Full Text] [Related]
26. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.
Hatano M; Eguchi J; Tatsumi T; Kuwashima N; Dusak JE; Kinch MS; Pollack IF; Hamilton RL; Storkus WJ; Okada H
Neoplasia; 2005 Aug; 7(8):717-22. PubMed ID: 16207473
[TBL] [Abstract][Full Text] [Related]
27. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
Yao Y; Luo F; Tang C; Chen D; Qin Z; Hua W; Xu M; Zhong P; Yu S; Chen D; Ding X; Zhang Y; Zheng X; Yang J; Qian J; Deng Y; Hoon DSB; Hu J; Chu Y; Zhou L
Cancer Immunol Immunother; 2018 Nov; 67(11):1777-1788. PubMed ID: 30159779
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
Curry WT; Gorrepati R; Piesche M; Sasada T; Agarwalla P; Jones PS; Gerstner ER; Golby AJ; Batchelor TT; Wen PY; Mihm MC; Dranoff G
Clin Cancer Res; 2016 Jun; 22(12):2885-96. PubMed ID: 26873960
[TBL] [Abstract][Full Text] [Related]
29. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine.
Okada H; Giezeman-Smits KM; Tahara H; Attanucci J; Fellows WK; Lotze MT; Chambers WH; Bozik ME
Gene Ther; 1999 Feb; 6(2):219-26. PubMed ID: 10435106
[TBL] [Abstract][Full Text] [Related]
30. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
Wen PY; Reardon DA; Armstrong TS; Phuphanich S; Aiken RD; Landolfi JC; Curry WT; Zhu JJ; Glantz M; Peereboom DM; Markert JM; LaRocca R; O'Rourke DM; Fink K; Kim L; Gruber M; Lesser GJ; Pan E; Kesari S; Muzikansky A; Pinilla C; Santos RG; Yu JS
Clin Cancer Res; 2019 Oct; 25(19):5799-5807. PubMed ID: 31320597
[TBL] [Abstract][Full Text] [Related]
31. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer.
Veelken H; Mackensen A; Lahn M; Köhler G; Becker D; Franke B; Brennscheidt U; Kulmburg P; Rosenthal FM; Keller H; Hasse J; Schultze-Seemann W; Farthmann EH; Mertelsmann R; Lindemann A
Int J Cancer; 1997 Jan; 70(3):269-77. PubMed ID: 9033626
[TBL] [Abstract][Full Text] [Related]
32. DCVax®-L--developed by Northwest Biotherapeutics.
Polyzoidis S; Ashkan K
Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
[TBL] [Abstract][Full Text] [Related]
33. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
34. Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy.
Okada H; Attanucci J; Tahara H; Pollack IF; Bozik ME; Chambers WH; Lotze MT
Cancer Gene Ther; 2000 Mar; 7(3):486-94. PubMed ID: 10766355
[TBL] [Abstract][Full Text] [Related]
35. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
[TBL] [Abstract][Full Text] [Related]
36. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
Prins RM; Wang X; Soto H; Young E; Lisiero DN; Fong B; Everson R; Yong WH; Lai A; Li G; Cloughesy TF; Liau LM
J Immunother; 2013 Feb; 36(2):152-7. PubMed ID: 23377664
[TBL] [Abstract][Full Text] [Related]
37. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
Belmans J; Van Woensel M; Creyns B; Dejaegher J; Bullens DM; Van Gool SW
Sci Rep; 2017 Oct; 7(1):13902. PubMed ID: 29066810
[TBL] [Abstract][Full Text] [Related]
39. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
40. DCVax-Brain and DC vaccines in the treatment of GBM.
Wheeler CJ; Black KL
Expert Opin Investig Drugs; 2009 Apr; 18(4):509-19. PubMed ID: 19335279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
